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New York, USAIntroduction: Measuring the chemokine CXCL9 in urine by enzyme-linked immunosorbent assay (ELISA)
can diagnose acute cellular rejection (ACR) noninvasively after kidney transplantation, but the required
12- to 24-hour turnaround time is not ideal for rapid, clinical decision-making.
Methods: We developed a biolayer interferometry (BLI)based assay to rapidly measure urinary
CXCL9 in <1 hour. We validated this new assay versus standard ELISA in 86 urine samples from
kidney transplantation recipients with various diagnoses. We then used BLI to analyze samples from
56 kidney transplantation recipients, including 46 subjects who experienced an acute rise in serum
creatinine associated with biopsy-proven ACR (n ¼ 22), subclinical rejection (n ¼ 15), or no infiltrates
(n ¼ 9), and 10 stable kidney transplantation recipients with surveillance biopsies. To assess its
usefulness in detecting adequacy of therapy we serially measured serum creatinine and urinary
CXCL9 in 6 subjects after treatment for ACR, and correlated the results with histological diagnoses on
follow-up biopsies.
Results: BLI accurately and reproducibly detected urinary CXCL9 in <1 hour. BLI-based results showed
that urinary CXCL9 was >200 pg/ml in subjects with ACR and #100 pg/ml in subjects with stable kidney
function without cellular infiltrates. In samples obtained after treatment for ACR, BLI CXCL9 measure-
ments detected biopsy-proven intragraft infiltrates despite treatment-induced reduction in serum
creatinine.
Discussion: Together, our proof-of-principle results demonstrate that BLI-based urinary CXCL9 detection
has potential as a point-of-care noninvasive biomarker to diagnose and guide therapy for ACR in kidney
transplantation recipients.
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published online 21 June 2017D espite reduction of acute cellular rejection (ACR)rates since the 1990s,1,2 ACR continues to affect
long-term kidney allograft survival negatively.3,4 A
few experienced centers perform follow-up biopsies
to assess efficacy of antirejection therapy, but this prac-
tice is impractical, risky, and therefore not done
routinely in most transplantation centers. NoninvasiveKidney International Reports (2017) 2, 1186–1193
I Gandolfini et al.: Rapid Detection of Urinary CXCL9 TRANSLATIONAL RESEARCHmonitoring tools capable of rapidly assessing intragraft
inflammation could guide therapeutic decision-making
following treatment for rejection and thereby poten-
tially improve graft function and patient health.
Urinary chemokines are among candidate bio-
markers for detecting kidney allograft inflammation.5,6
CXCL9 is an interferon-ginduced, T-cell chemo-
attractant chemokine produced by monocyte/macro-
phages, endothelial cells, and renal parenchymal cells.7
Results of single-center studies8–14 showed that mea-
surements of urinary CXCL9 (uCXCL9) can differentiate
ACR from most other causes of acute post-
transplantation kidney dysfunction in the absence of
infection. Findings from Clinical Trials in Organ
Transplantation (CTOT)-01 (NCT01974999), a prospec-
tive, multicenter, observational study of 280 kidney
transplantation recipients (KTRs) showed that uCXCL9
(by enzyme-linked immunosorbent assay [ELISA]) at a
threshold of $200 pg/ml, diagnosed ACR at the time of
an acute elevation of serum creatinine (negative pre-
dictive value: 92%, positive predictive value: 67%).12
Excluding subjects with BK virus (BKV) or urinary
tract infection increased the positive predictive value
to >80%.12 In a follow-up tacrolimus withdrawal trial
(CTOT-09, NCT01517984), serial ELISA uCXCL9 mea-
surements detected ACR 3 to 30 days before clinical
presentation.14 The 12- to 24-hour requisite turnaround
time for ELISAs is not ideal for “real-time” imple-
mentation of therapeutic changes based on assay
results.
Herein we report an alternative, automated, point-
of-care uCXCL9 assay that can be performed in <1
hour. In addition to confirming that this innovative
technology can diagnose ACR noninvasively, we pro-
vide proof of concept that serial uCXCL9 measurements
following therapy for ACR could be used to guide
subsequent clinical decision-making.MATERIALS AND METHODS
Samples and Patients
Aliquots of stored BKV-negative urine samples were
obtained from 2 multicenter, prospective, observational
kidney transplantation studies, CTOT-0112 and CTOT-
08 (www.ctot.org, NCT01289717). These samples (n ¼
86) were used to compare a biolayer interferometry
(BLI) assay and ELISA (Figure 1).
We also prospectively collected serial urine samples
and clinical data from 46 KTRs with for-cause biopsies
who were followed at 4 institutions (Bellvitge Univer-
sity Hospital, IDIBELL, UB, Barcelona, Spain; Mount
Sinai Hospital, New York, New York, USA; Parma
University Hospital, Parma, Italy; and S. Orsola Uni-
versity Hospital, Bologna, Italy). We also analyzedKidney International Reports (2017) 2, 1186–1193urine from 10 BKV-negative subjects with stable serum
creatinine and no intragraft infiltrates at 6-month sur-
veillance biopsies. Consenting subjects were enrolled at
the time of biopsy. The initial urine sample was ob-
tained before the biopsy and before any antirejection
treatment.
Inclusion criterion was an acute increase in serum
creatinine $30%. Patients with pure antibody-
mediated rejection,15 as reported by the local patholo-
gist, were excluded. Immunosuppression varied by site
but generally included induction with antithymocyte
globulin (ATG) or anti-CD25 monoclonal antibody
(mAb) and maintenance immunosuppression with a
calcineurin inhibitor, and mycophenolic acid with or
without corticosteroids. Therapeutic interventions were
made at the discretion of the site investigators and were
not dictated by study. Therapy of ACR included ste-
roids, ATG, and/or i.v. Ig Serum creatinine values were
determined at each hospital laboratory, and the infor-
mation was collected from hospital records of the sub-
jects. Surveillance studies for viral infections, including
the BK virus, were performed according to local practice
at each participating site. Bacterial (e.g., urinary) and BK
virus infections were routinely tested for in patients
with acute renal allograft dysfunction as per local stan-
dard of care. Patients included in the study were nega-
tive for BK virus infection. The enrollment and sample
and/or data collection were performed following insti-
tutional review board approval at each site. All patients
signed informed consent.
Laboratory Studies
Urine samples for chemokines were centrifuged at
2000g for 30 minutes at 4 C within 4 hours of collec-
tion. The supernatant was divided into aliquots and
frozen at 80 C.
Urine ELISA for CXCL9
Frozen aliquots of urine supernatant were diluted (1:1)
in 0.05% Tween 20/0.4% bovine serum albumin (BSA)
in phosphate-buffered saline (PBS) (pH 7.2–7.4), and
tested by ELISA for CXCL9 (R&D Systems, Minneap-
olis, Minneapolis) as reported.12,14
Urine CXCL9 detection by BLI
Samples were run on OctetRED96 using Octet Data
Acquisition software (version 8.2, Pall ForteBio LLC,
Fremont, CA) and analyzed using Data Analysis soft-
ware (version 8.2, Pall ForteBio LLC), while continually
monitoring wavelength. Assays were performed in
black 96-well plates. All steps used a shake speed of
1000 rpm unless otherwise specified. All wells con-
tained 200 ml of fluid. Streptavidin-conjugated sensor
tips (Pall ForteBio LLC, cat #18-5019) were incubated in1187
Figure 1. Biolayer interferometry (BLI) rapidly detects uCXCL9. (a) Schematic representation of assay (top) with primary readout depicting light
wavelength shift with each step (y-axis) over time (x-axis) using 62.5 to 1000 pg/ml of recombinant CXCL9 (each colored line is a different
concentration) as a standard curve. (b) Bland-Altman plot of CXLC9 as measured by standard enzyme-linked immunosorbent assay (ELISA)
versus BLI. The x-axis is on a logarithm scale to allow visualization of the numerical range close to the positivity threshold of the assays (i.e., 200
pg/ml). Symbols represent different diagnoses. Horizontal dashed lines represent the mean difference of ELISA and BLI results, horizontal solid
lines represent the 95% limits of agreement, which are defined as the mean difference 1.96  the SD of the differences. Red lines include all
the data points; blue lines are drawn after exclusion of mean values >500 pg/ml. The numerical values of the limits of agreement are reported
above or below the respective lines. (c) Scatterplot of CXCL9 results as performed by ELISA versus BLI (logarithm scale). The solid line passing
through the origin with a 45-degree angle represents the line of perfect concordance between ELISA and BLI. Dashed lines passing through 200
pg/ml divide the plot into 4 quadrants. Note that all results lie in the lower left quadrant or in the upper right quadrant, both representing areas of
agreement between the 2 methods. Points within the upper left quadrant represent instances in which BLI results are positive (i.e., >200 pg/ml)
but standard ELISAs are negative (i.e., <200 pg/l), whereas points within the lower right quadrant would represent instances in which BLI
results are negative and ELISA results are positive (note, there are no points in either of these 2 quadrants). (d) BLI-ELISA for CXCL9 does not
detect recombinant CXCL10. Each bar is the mean of 3 replicate values; P values show unpaired t-tests. Assay was repeated with similar results.
Statistical comparisons performed by t-test. AAMR, acute antibody-mediated rejection; ACR, acute cellular rejection; CAMR, chronic antibody-
mediated rejection; CCR, chronic cellular rejection.
TRANSLATIONAL RESEARCH I Gandolfini et al.: Rapid Detection of Urinary CXCL9PBS (pH 7.2–7.4) containing 0.025% Tween 20/0.4%
BSA for 10 minutes and then incubated with 20 mg/ml
(in the previously described buffer) biotinylated mouse
antihuman CXCL9 (clone B8-11, BD Bioscience, San
Jose, CA) for 10 minutes. Following a 30-second wash,
the tips were exposed for 30 minutes to urine1188supernatants diluted 1:1 with PBS/Tween/BSA or to
recombinant CXCL9 (62.5–500 pg/ml, R&D Sys.
cat#DY392) diluted in PBS/Tween/BSA to calculate a
standard curve. Urine samples obtained from healthy
subjects (institutional review boardapproved collec-
tion of urine from normal volunteers at Mount SinaiKidney International Reports (2017) 2, 1186–1193
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an additional 30-second wash, the sensor tips were
exposed to horseradish peroxidase (HRP)conjugated
antihuman CXCL9 clone B8-6 (5 mg/ml in PBS/Tween/
BSA for 15 min). The tips were washed in stable
peroxide buffer (3,3’-diaminobenzidine, DAB substrate
kit, Thermo Fischer Scientific, Canoga Park, CA, cat
#PI-34065) for 30 seconds on a shaker at 200 rpm and
then exposed to metal-enhanced DAB diluted into
peroxide buffer for 15 minutes.
Statistical Methods
Data are summarized using descriptive statistics for
categorical (counts/percentages) and continuous (mean
and SDs) variables. To assess the agreement between BLI
and standard ELISA measurements of CXCL9, we used
the Lin’s concordance correlation coefficient (the
concordance correlation coefficient combines measures
of both precision and accuracy to determine how far the
observed data deviate from the line of perfect concor-
dance)16 and Bland and Altman’s 95% limits-of-agree-
ment17 in urine samples from 86 kidney transplantation
patients with various biopsy diagnoses. Bland-Altman’s
95% limits of agreement were additionally computed
after exclusion of values of CXCL9 >500 pg/ml because
close agreement between BLI and ELISA with respect to
such large CXCL9 values was not relevant for the pur-
pose of clinical decision-making. The intraplate assay
coefficient of variation (CV) was calculated based on the
wavelength shift for samples of recombinant CXCL9
diluted in both PBS/Tween/BSA and urine from healthy
subjects, with 4 replicates for each dilution on the same
plate. The average of the CVs at each dilution is reported
as the intra-assay CV. The interplate CV is calculated
based on the mean CV of the different dilutions, with 4
replicates on one plate, repeated 3 times during 1 week.
Differences in CXCL9 values were analyzed by Mann-
Whitney test (Prism, GraphPad Software, La Jolla, Cal-
ifornia). A 2-tailed P value <0.05 was considered to be
statistically significant.
RESULTS
To shorten the time required to detect uCXCL9, we used
BLI, a methodology in which binding of a ligand to a
fiber optic sensor tip induces a real-time detectable
wavelength shift in the returning beam of light (Dl) that
correlates with the quantity of bound ligand.18 BLI has
been used to screen mAb binding affinities among other
indications.18 We chose BLI over other available rapid
detection systems, including nanoscale and/or micro-
fluidic andmultiplexing approaches such as Ella (https://
www.proteinsimple.com/ella.html) or Gyros (http://
www.bioagilytix.com/gyrolab-for-frequent-automated-
sampling), because urine volumes are not limitingKidney International Reports (2017) 2, 1186–1193(negating the need for nanoscale volumes), high-
throughput multiplexing is not required for CXCL9
analysis of clinical samples, the BLI technology is more
widely available, and the ability to move BLI technology
to a point-of-care clinical setting seems straightforward.
We adapted BLI to detect CXCL9 (Figure 1a) by
attaching an anti-CXCL9 mAb to commercially available
sensor tips, exposing the tips to CXCL9 and amplifying
the signal with a second, HRP-conjugated anti-CXCL9
mAb followed by addition of a metal-enhanced HRP
substrate. Using precoated sensor tips, the assay can be
completed in <1 hour (Figure 1a). We measured CXCL9
by ELISA and BLI in 86 urinary samples from patients
with various biopsy diagnoses.
A Bland-Altman plot17 (Figure 1b) analysis showed
good agreement between the 2 assays for values <500
pg/ml; the average difference between ELISA and BLI
was 66  41 pg/ml and the 95% limits of agreement
were 147 to þ14 pg/ml. Depiction of the same data
using a scatterplot comparison of ELISA and BLI results
(Figure 1c) showed a Lin’s concordance correlation
coefficient16 of 0.78 (BLI was more sensitive than
ELISA) and a 100% concordance of positive results
versus negative results based on the threshold of 200
pg/ml.
Specificity controls using independent samples
showed that the BLI CXCL9 assay did not cross-react
with CXCL10 (Figure 1d). BLI had the same limit of
sensitivity as reported for commercial ELISAs (w35 pg/
ml, see data sheet, R&D catalogue #DY392) with intra-
and interplate CVs of <5% and <12%, respectively
(data not shown).
We then measured uCXCL9 by BLI in a different set
of samples obtained from 56 BKV-negative KTRs. This
new set included 22 samples from subjects with
a $30% increase serum creatinine and biopsy-proven
ACR $ Banff 1A (Table 1). Urinary CXCL9 was >200
pg/ml in all of these samples (Figure 2). In contrast,
uCXCL9 was <100 pg/ml (P < 0.01 vs. ACR) in stored
CTOT urine samples from 10 BKV-negative KTRs with
stable serum creatinine and a normal 6-month surveil-
lance biopsy (Table 1 and Figure 2). Urine CXCL9
values in samples from BKV-negative subjects (n ¼ 9)
with an acute rise in serum creatinine due to calci-
neurin inhibitor toxicity and/or volume depletion, but
without mononuclear cell infiltrates, were all 100 to 200
pg/ml (P < 0.01 vs. ACR or vs. normal) (Figure 2).
CXCL9 measurements in prospectively collected urine
from BKV-negative subjects with for-cause biopsies
that showed biopsy-proven borderline rejection
(n ¼ 15) (Table 1) were higher than those from biopsies
without infiltrates (P < 0.01) (Figure 2); 7 of
15 contained $200 pg/ml CXCL9 and 8 showed <200
pg/ml (Figure 2).1189
Table 1. Baseline demographic and clinical characteristics of study subjects
Characteristics
Overall
(n [ 56)
No infiltratesa
(n [ 10)
No infiltrates
(n [ 9)
Borderline
(n [ 15)
ACR
(n [ 22)
Donors
Deceased 30 (53.6) 2 (20.0) 5 (55.6) 11 (73.3) 12 (54.6)
Male 22 (39.3) 3 (30.0) 2 (22.2) 6 (40.0) 11 (50.0)
Age (yr) 37.5  15.6 34.9  11.5 32.9  15.2 41.0  14.9 38.3  18.5
Race
Black or African American 10 (17.9) 3 (30.0) 3 (33.0) 2 (13.3) 2 (9.1)
Other race 27 (48.2) 5 (50.0) 5 (55.6) 9 (60.0) 8 (36.4)
Unknown or not reported 19 (33.9) 2 (20.0) 1 (11.1) 4 (26.7) 12 (54.5)
Recipients
Male 42 (75.0) 6 (60.0) 6 (66.7) 12 (80.0) 18 (81.8)
Age (yr) 45.4  18.3 45.6  9.8 45.8  21.7 47.1  19.7 44.0  19.8
Race
Black or African American 19 (33.9) 5 (50.0) 2 (22.2) 5 (33.3) 7 (31.8)
Other race 27 (48.2) 5 (50.0) 2 (22.2) 8 (53.3) 12 (54.5)
Unknown or not reported 10 (17.9) 0 (0.0) 5 (55.6) 2 (13.3) 3 (13.6)
Induction
Yes 52 (92.9) 8 (80.0) 8 (88.9) 15 (100.0) 21 (95.5)
No 4 (7.1) 2 (20.0) 1 (11.1) 0 (0.0) 1 (4.5)
Time after transplantb 183 (70–211) 191 (186–197) 167 (79–211) 125 (28–-190) 120 (76–597)
ACR, acute cellular rejection.
aPatients with stable graft function who underwent surveillance biopsies. All the other patients received a biopsy for cause (serum creatinine increase >30%).
bDays from transplant to the date of first graft biopsy.
Variables are expressed as mean  SD, median (interquartile range), or absolute number (%).
TRANSLATIONAL RESEARCH I Gandolfini et al.: Rapid Detection of Urinary CXCL9In addition, we collected and analyzed serial urine
samples from 6 BKV-negative KTRs with ACR before
and after antirejection therapy, and who had follow-up
biopsies as part of clinical care. The summarized results
from 1 representative subject at 20 days afterFigure 2. Biolayer interferometry urine CXCL9 detects intragraft
infiltrates in kidney transplant recipients. We analyzed 56 samples
from kidney transplant recipients with surveillance (open circles, n¼
10) or for-cause (filled circles; $30% increase in serum creatinine)
biopsies. Subjects were stratified according to the presence of stable
graft function and no graft infiltrates (in surveillance biopsies, n¼ 10),
acute graft dysfunction and no graft infiltrates (n ¼ 9), borderline
rejection (n ¼ 15), or acute cellular rejection (ACR) (in for-cause bi-
opsies, n¼ 22). Dotted red line is drawn at the 200 pg/ml threshold for
CXCL9 positivity. Horizontal black lines are drawn at the median value
for each group. Statistical comparison performed by aMann-Whitney
test. *P < 0.05; **P < 0.01.
1190transplant are depicted in Figure 3. The subject’s
baseline serum creatinine was 1.0 mg/dl and increased
to 7.2 mg/dl coincident with an episode of biopsy-
proven ACR. Steroid pulses reduced serum creatinine
levels to <2 mg/dl, but follow-up biopsies on days 7
and 28 after the initial diagnostic biopsy showed
intragraft infiltrates associated with persistently
elevated levels of uCXCL9. In 2 additional subjects
(Figure 4a and b), antirejection therapy resulted in
uCXCL9 <200 pg/ml and absence of mononuclear in-
filtrates in follow-up biopsies. In 3 cases (Figure 4ce),
persistent uCXCL9 >200 pg/ml despite therapy for
ACR was associated with intragraft infiltrates, regard-
less of changes in serum creatinine.
DISCUSSION
We demonstrated that BLI and ELISA could similarly
detect uCXCL9, but BLI was considerably faster and
largely automated. These advantages could permit
implementing BLI-based uCXLC9 testing in a clinical
transplantation practice. Although BLI methods are
straightforward, the currently available detection
device has a complex and expensive interface designed
for broader use. Nonetheless, modifications could
simplify the interface and lower costs to accommodate
practicing physicians.
We showed that in BKV-negative KTRs with acute
graft dysfunction, BLI-measured uCXCL9 $200 pg/ml
detected Banff grade$1A ACR. Approximately 50% of
subjects with borderline and/or suspicious rejectionKidney International Reports (2017) 2, 1186–1193
Figure 3. Persistently elevated uCXCL9 after treatment for acute cellular rejection (ACR) detects subclinical intragraft infiltrates despite a
progressive decline in serum creatinine. (a) Clinical course depicting changes in serum creatinine and uCXCL9 (day 0 is the date of the biopsy,
20 days posttransplant). Colored horizontal bars depict time during which each drug was administered (key: upper right panel a). Blue star
represents the nadir serum creatinine within the initial 6 months posttransplant. Red dashed line is drawn at the 200 pg/ml threshold for CXCL9
positivity. (bd) Representative periodic acid–Schiff stained sections of biopsy 1 (Bx1), 2 (Bx2), and 3 (Bx3) depicted in (a) showing areas of
mononuclear cell infiltration in each biopsy. (e) Quantitative Banff scores as read by the local pathologist for the 3 biopsies.
I Gandolfini et al.: Rapid Detection of Urinary CXCL9 TRANSLATIONAL RESEARCHalso had uCXCL9 >200 pg/ml, with the remainder
falling into the normal range. Because (i) histological
diagnoses in kidney transplantation are subject to
sampling bias and inter-reader variation, and (ii) the
significance of borderline rejection remains controver-
sial,19,20 one testable hypothesis that arose from these
observations was that elevated uCXCL9 measurements
were better indicators of ongoing pathological inflam-
mation than serum creatinine or histological evidence
of suspicious and/or borderline rejection. Although
urinary tract infections and BKV increase uCXCL9,
routine BKV monitoring and urinalysis together with
rapid CXCL9 diagnostics could guide clinical decision-
making noninvasively, a hypothesis that is also
testable.
We acknowledge that none of the tested subjects in
this series had pure antibody-mediated rejection. Other
groups showed associations between antibody-mediatedKidney International Reports (2017) 2, 1186–1193rejection and the chemokine CXCL10 (in the absence of
CXCL9).10,21 Pilot studies indicated that we could detect
CXCL10 by an analogous BLI-based ELISA (data not
shown), which provided feasibility for potentially
incorporating both CXCL9 and CXCL10 measurements
into clinical care.
We also provided evidence that serial uCXCL9
monitoring after initiating treatment for ACR could be
diagnostically informative. In our limited analysis of
KTRs with clinically indicated follow-up biopsies,
continuous elevation of uCXCL9 detected persistent
intragraft cellular infiltrates regardless of serum creat-
inine. We acknowledge the small numbers of subjects,
the inconsistent numbers and timing of biopsies,
and the descriptive nature of this case study pre-
cluded reaching definitive conclusions regarding the
usefulness of BLI uCXCL9 to guide post-treatment
decision-making in KTRs with rejection. Nonetheless,1191
Figure 4. Changes in serum creatinine and urine CXCL9 in 5 BK virus–negative, donor specific antibody–negative subjects (depicted individually
in a–e) with acute cellular rejection and follow-up biopsies to monitor treatment efficacy. Tables below each panel depict Banff scores of each
of the biopsies. Dotted red line is drawn at the 200 pg/ml threshold for CXCL9 positivity. ATG, antithymocyte globulin.
TRANSLATIONAL RESEARCH I Gandolfini et al.: Rapid Detection of Urinary CXCL9these proof-of-concept results provided a foundation to
support future controlled studies to test the hypothesis
that inclusion of real-time BLI uCXCL9 measurements
would lower the need for follow-up biopsies, guide
decisions to continue and/or alter antirejection therapy,
and consequently, improve patient outcomes.
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